Danish Avilex Pharma wants to create first stroke treatment since 1987

Danish Avilex Pharma is about to initiate its first phase I trial with a candidate against ischemic stroke - an indication CEO Kristian Strømgaard calls the "graveyard of biotech."

Photo: Avilex Pharma

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles